دورية أكاديمية
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
| العنوان: | Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab |
|---|---|
| المؤلفون: | Magro, Fernando, Lopes, Susana, Silva, Marco, Coelho, Rosa, Portela, Francisco, Branquinho, Diogo, Correia, Luís, Fernandes, Samuel, Cravo, Marília, Caldeira, Paulo, Tavares de Sousa, Helena, Patita, Marta, Lago, Paula, Ramos, Jaime, Afonso, Joana, Redondo, Isabel, Machado, Patrícia, Philip, George, Lopes, Joanne, Carneiro, Fátima |
| بيانات النشر: | SAGE Publications |
| سنة النشر: | 2019 |
| المجموعة: | Repositório Científico do Centro Hospitalar do Porto |
| مصطلحات موضوعية: | endoscopic activity, golimumab, histological activity, serum soluble ST2, ulcerative colitis |
| الوصف: | Background: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab. Methods: We conducted an open-label single-arm multicentre prospective study. At screening/baseline, week 6 (W6) and week 16 (W16), clinical and endoscopic activity (total Mayo score), histologic activity (Geboes index) and biomarkers were evaluated. Results: From 38 patients, 34 (89.5%) completed W6 and 29 (76.3%) completed W16. Mean age (±SD) was 34.6 ± 12.6 years; 55.9% were female. At W16, 62.1% achieved clinical response. Patients with endoscopic activity at W6 (n = 20) had higher baseline sST2 (median, 24.5 versus 18.7 ng/ml, p = 0.026) and no decrease from baseline (median change, 0.8 versus -2.7, p = 0.029). At W6, sST2 levels correlated with endoscopic activity (rs = 0.45, p = 0.007) but not with histological activity (rs = 0.25, p = 0.151). The best cut-offs for endoscopic activity were sST2 = 16.9 ng/ml (sensitivity = 85%; specificity = 71%) and faecal calprotectin (FC) = 353 μg/g (sensitivity = 90%, specificity = 67%). Patients with histological activity at W6 (n = 27) had higher baseline ST2 levels (median, 23.0 versus 13.7 ng/ml, p = 0.035). sST2 did not correlate with FC or serum C-reactive protein. FC levels correlated with histological activity and baseline FC were higher when Geboes ⩾3.1 at W6. Conclusions: sST2 may be a surrogate biomarker of UC activity and therapeutic response as it correlates with endoscopic and clinical activity at W6 of golimumab treatment, and subjects with endoscopic and histological activity at W6 had higher baseline ST2 levels. ; This work was supported by Merck Sharp and Dohme, Lda, Portugal, which provided drug and financial support for the interventional study (Protocol Nr MK8259-22) ; info:eu-repo/semantics/publishedVersion |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1756-283X 1756-2848 |
| العلاقة: | Magro F, Lopes S, Silva M, et al. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol. 2019;12:1756284819869141. Published 2019 Aug 30. doi:10.1177/1756284819869141; http://hdl.handle.net/10400.16/2449Test |
| DOI: | 10.1177/1756284819869141 |
| الإتاحة: | https://doi.org/10.1177/1756284819869141Test http://hdl.handle.net/10400.16/2449Test |
| حقوق: | openAccess ; http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: | edsbas.7706D66B |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 1756283X 17562848 |
|---|---|
| DOI: | 10.1177/1756284819869141 |